|
Integritas Communications |
Share:
|
OverviewCOMMITTED TO THE DESIGN, DEVELOPMENT, AND DELIVERY OF INNOVATIVE AND CREATIVE EVIDENCE-BASED EDUCATION PROGRAMS |
ASCVD Clinical Research Updates Targeting Residual Inflammation in Patients with ASCVD and CKD
Emerging evidence and scientific advancements are revealing pathophysiologic mechanisms correlated with systemic inflammation and the development of atherosclerotic cardiovascular disease (ASCVD). Patients with chronic kidney disease (CKD) are at high risk for developing ASCVD. Novel anti-inflammatory therapies are showing efficacy at reducing inflammation and development of ASCVD, and are addin...
|
|
Chronic Rhinosinusitis with Nasal Polyps Navigating New Pathways to Better Patient Outcomes
Chronic inflammatory diseases of the upper and lower airways, especially CRSwNP and asthma, have been tied to significant risks and burdens for affected patients and frequently require close coordinated multidisciplinary care. Targeted agents designed to interrupt inflammatory cytokine signaling have been examined in clinical trials and evidence suggests these options can provide a range of bene...
|
|
Making The Call in Lower-Risk MDS Exploring Treatments That Improve Outcomes & Decrease Transfusion Burden
Myelodysplastic syndromes (MDSs) are among the most common hematologic malignancies and are characterized by their risk of progression to acute leukemia. Although patients with lower-risk MDS (LR-MDS) have longer life expectancies compared to those with high-risk disease, their disease course is not without challenges. In fact, symptoms related to anemia are very common in this population and le...
|
|
Managing Obesity in Adolescent Patients Your Top 10 Questions Answered
The rate of obesity in children and adolescents is increasing, posing significant physical and mental health challenges through childhood and adolescence and into adulthood. Recently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been approved for use in patients as young as 12 years, and it is critical that clinicians initiate both lifestyle management and pharmacologic therapies a...
|
|